Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma.
The claim by Adam Steensberg follows a 100 per cent surge in the company’s share price in the past year as investors bought the stock thanks to the potential of its anti-obesity drugs.
Zealand’s products in development will have to compete with the popular Wegovy and Zepbound drugs already on the market and made by Novo Nordisk and Eli Lilly respectively, which suppress appetite.
您已阅读14%（572字），剩余86%（3432字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。